CareDx Health (CDNA): רווח נקי למניה (EPS TTM)

Profit dependence on AlloSure and AlloMap genomic test sales may create volatility, as evidenced by CareDx, Inc (CDNA) TTM net income per share, where the latest parameter is 2.38. However, the digital health monitoring environment makes CareDx, Inc (CDNA) an indispensable partner for clinics. A stable moat and the integration of molecular diagnostics into medical standards securely protect the business's position.

CareDx, Inc (CDNA) diversification across organ transplantation sectors and the implementation of digital software minimize profit dependence on local changes in medical protocols. By analyzing the rolling net income per share trend, an investor sees the final annual financial result divided by the total number of securities, which allows for an objective assessment of the real return on each ownership stake and capital stability.